Benzinga | Jan 12, 2021 05:09AM EST

Travere Therapeutics on Monday Received FDA Orphan Drug Designation for Sparsentan for Treatment of immunoglobulin A (IgA) nephropathy

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=614417